Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Brukinsa
(United States) [Available]Synonyms :
zanubrutinib 
Class :
Antineoplastics and Tyrosine Kinase Inhibitor
Brand Name :
Brukinsa
(United States) [Available]Synonyms :
zanubrutinib 
Class :
Antineoplastics and Tyrosine Kinase Inhibitor
160
mg
Capsule
Oral
twice a day
Continue the therapy until disease progression or unacceptable toxicity occurs 
Dose Adjustments
Mild to severe: No adjustment recommended
Safety and efficacy are not studied
Refer adult dosing  
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Zanubrutinib
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Zanubrutinib
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Zanubrutinib
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Zanubrutinib
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Zanubrutinib
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 Inhibitors
when both drugs are combined, there may be increase in the effect of immunosuppressants 
the effect of zanubrutinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zanubrutinib 
CYP3A4 inducers decrease the concentration of zanubrutinib in serum
when both drugs are combined, there may be a decrease in the therapeutic effect
aminosalicylic acid derivatives
it may increase the effect of myelosuppressive agents 
immunosuppressants may reduce the therapeutic effect of pneumococcal vaccines 
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
may have an increasingly adverse effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
It may enhance the risk of bleeding by affecting coagulation when combined with omega-3 carboxylic acids
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
zanubrutinib: they may increase the antiplatelet effect of antiplatelet agents
zanubrutinib: they may increase the antiplatelet effect of antiplatelet agents
zanubrutinib: they may increase the antiplatelet effect of antiparasitic agents
zanubrutinib: they may increase the antiplatelet effect of antiparasitic agents
zanubrutinib: they may increase the antiplatelet effect of antiparasitic agents
zanubrutinib: they may increase the antiplatelet effect of antiparasitic agents
methoxypolyethylene glycol-epoetin betaÂ
combining zanubrutinib with methoxy polyethylene glycol-epoetin beta can raise the risk or severity of thrombosis
dihydroergocristine can decrease the metabolism of zanubrutinib when combined with it
when used with fosnetupitant, the metabolism of zanubrutinib may be slowed
the metabolism of zanubrutinib may see an increase when combined with butalbital
idelalisib increases the effect or level of zanubrutinib by altering the intestinal/hepatic CYP3A4 metabolism
metronidazole enhances the effect of zanubrutinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
may enhance the toxic effect of anti-coagulants
Adverse drug reactions:  Â
Frequency defined  Â
>10%: Â
hypokalemia Â
increased serum glucose Â
 increased serum potassium Â
Abdominal pain Â
constipation Â
diarrhea Â
nausea Â
vomiting Â
Urinary tract infection Â
Contraindication:Â
None Â
Caution:Â
InfectionsÂ
HemorrhageÂ
Cardiac arrhythmiasÂ
HepatotoxicityÂ
Pregnancy warnings:    Â
Pregnancy Categories:      Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.      Â
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women      Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women      Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits      Â
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.      Â
Category N: There is no data available for the drug under this category
B cell receptors expressed on the peripheral B cell surface are signaled by the non-receptor kinase bruton’s tyrosine kinase (BTK).Â
It reduces the size of the tumor in mantle cell lymphoma by preventing the growth and survival of cancerous B cells.Â
In many B cell malignancies, the BCR signaling pathway is essential for both the proliferation and survival of malignant B cells as well as for normal B-cell growth.Â
BTK is inhibited by zanubrutinib by the formation of a covalent link with the cysteine 481 residue in the enzyme’s active site, the adenosine triphosphate (ATP)–binding pocket.Â
It is taken orally in capsule form with or without food.Â
Swallow capsules whole at time and do not open or dissolve it.Â
If the patient misses a dose, take the following dose at the scheduled time instead.Â
Patient Information Leaflet Â
Generic Name: zanubrutinib (Rx)Â
Pronounced: za-nu-bru-ti-nibÂ
Why do we use zanubrutinib?Â
zanubrutinib is an anticancer drug used to treat mantle cell lymphoma and inhibit the growth and spread of cancer cells.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
